Citations

Clear

45 citation(s) found for "Serra, P".

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report
Al‐Samkari, Hanny , Kasthuri, Raj S. , Mager, Hans‐Jurgen, Zhou, Jenny Y. , Serra, Marcelo M. , Samuelson‐Bannow, Bethany T., Doren, Layla N Van , Piccirillo, Jay F. , Clancy, Marianne S. , Thomas, Sonia , Riera‐Mestre, Antoni , Gossage, James R. , Hermans, Cédric , Hammill, Adrienne M. , Drygalski, Annette von , Olitsky, Scott E., Faughnan, Marie E. , Sewaralthahab, Sarah , Iyer, Vivek N , Al-Samkari, Hanny , Hammill, Adrienne , Kasthuri, Raj S , Thomas, Sonia M , McCrae, Keith R. , Pishko, Allyson M. , Iyer, Vivek , Winship, Ingrid , Mei‐Zahav, Meir

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 10 | Pages: 1813-1827

10.1002/ajh.70011 | PMID 40662351 Get It

ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
Metabolic Dysfunction–Associated Steatotic Liver Disease—The New Epidemic of Chronic Liver Disease
Serra‐Burriel, Miquel , Kamath, Patrick S. , Ginès, Pere

Mayo Clinic

JAMA Network Open | June 17, 2025 | Volume: 8 | Issue: 6 | Pages: e2516381

10.1001/jamanetworkopen.2025.16381 | PMID 40526389 Get It

Development of a prognostic score for stage IV NSCLC using advance machine learning algorithms: An international comparative study across South Korea, US, and France.
Lee, Daehwan , Hwang, Gyeongjo , Grossiord, Éloïse, Blanchon, Margot, Frau, Francesca , Hernández, Ramón Díaz , Sarkar, Somnath, Jung, Hyun Ae, Serra, Mercedes , Hernandez, Ramon, Sarkar, Somnath, Parikh, Kaushal , Jung, Hyun Ae

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e20615 Get It

e20615 Background: Patients with Stage IV NSCLC have a poor prognosis, with approximately 25-30% succumbing to the disease within the first three months. However, survival outcomes can vary significantly depending on individual factors and advancements in treatment options. Therefore, it is crucial to identify patients at high risk of poor survival outcomes to tailor personalized treatment strategies and optimize clinical management. An international study has been conducted to generate prognostic scores for patients with Stage IV NSCLC. Methods: A retrospective observational study was conducted using real-world data (RWD) from South Korea (ROOT-HEALTH database from Samsung Medical Center), the USA (COTA NSCLC dataset) and France (CIAN lung cohort from Centre Léon Bérard). Patients with stage IV NSCLC between January 2008 and December 2023 were included. The study's primary objective was to learn from patients ‘baseline characteristics affecting overall survival (OS) and progression-free survival (PFS) to derive a prognostic score reflecting relative risk of death for given patient. A partition strategy was used, with 70% of the cohort for training and 30% for validation. Data-driven feature elimination has been applied to avoid overfitting of the models. Nested cross-validation reduced selection bias in hyperparameter tuning and model selection. Results: A total of 7,805 patients with NSCLC were included in the final analysis (USA: n=610, France: n=271, Korea: n=6,924). In the Korean dataset, the model achieved a C-index of 0.872 for OS using 35 selected variables. For the USA dataset, the model, based on 15 selected variables, demonstrated a C-index of 0.707 for OS. For PFS, the Korean dataset demonstrated a C-index of 0.823, the USA dataset achieved a C-index of 0.664, and the French dataset reported a C-index of 0.64, using 15 selected variables. The important predictors for OS included albumin, neutrophil/lymphocyte ratio, bilirubin, and druggable mutations. For PFS, important predictors included LDH, albumin, hemoglobin, MET mutation, bilirubin, and BMI. The prognostic scores derived from these models allowed to identify patients with higher risk of death, than average, in each country. Conclusions: This study generates prognostic scores for OS and PFS in stage IV NSCLC using longitudinal international data from the USA, France, and South Korea throughout the cancer journey. It has the potential to support better treatment strategy for severe patients in clinical practice and early decision-making in clinical studies. Further research utilizing diverse international cohorts is essential to refine prognostic scores and enhance personalized treatment strategies for stage IV NSCLC patients.
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer
Compadre, Amanda, Drexler, Rebecca, Loeb, Megan, Rodriguez, Kevin, Brill, Joshua, Harrington, Shariska P. , Sandoval, Carmen, Sanders, Brooke E. , Kuroki, Lindsay M. , Hagemann, Andrea R. , Powell, Matthew A. , Walts, Ann E. , Karlan, Beth, Oršulić, Sandra , Zhao, Peinan , Khabele, Dineo , Harrington, Shariska, Schab, Angela M. , Compadre, Amanda J. , Drexler, Rebecca, McCourt, Carolyn Kay , Thaker, Premal H. , Mutch, David G. , Serra, Violeta , Hagemann, Ian S. , Fuh, Katherine Cynthia , Sun, Lulu , Verma, Priyanka , Lomonosova, Elena , Mullen, Mary Margaret

Mayo Clinic

Journal of Clinical Investigation | May 20, 2025 | Volume: 135 | Issue: 13 | Pages: No page available

10.1172/jci189511 | PMID 40392598 Get It

BACKGROUND Treatment of tubo-ovarian high-grade serous carcinoma (HGSC) includes cytoreductive surgery, platinum-based chemotherapy, and often poly(ADP-ribose) polymerase (PARP) inhibitors. While homologous recombination (HR) deficiency is a well-established predictor of therapy sensitivity, over 50% of HR-proficient HGSCs also exhibit sensitivity. Currently, there are no biomarkers to identify which HR-proficient HGSCs will be sensitive to standard-of-care therapy. Replication stress may serve as a key determinant of response. METHODS We evaluated phospho–RPA2-T21 (p-RPA2) foci via immunofluorescence as a biomarker of replication stress in formalin-fixed, paraffin-embedded HGSC samples collected at diagnosis from patients treated with platinum chemotherapy (discovery cohort, n = 31; validation cohort, n = 244) or PARP inhibitors ( n = 63). Recurrent HGSCs ( n = 38) were also analyzed. p-RPA2 score was calculated using automated imaging analysis. RESULTS Samples were defined as p-RPA2-high if more than 16% of cells had ≥2 p-RPA2 foci on automated analysis. In the discovery cohort, HR-proficient, p-RPA2-high HGSCs demonstrated significantly higher rates of a chemotherapy response score of 3 to platinum chemotherapy than HR-proficient, p-RPA2-low HGSCs. In the validation cohort, patients with HR-proficient, p-RPA2-high HGSCs had significantly longer survival after platinum treatment than those with HR-proficient, p-RPA2-low HGSCs. Additionally, the p-RPA2 assay effectively predicted survival outcomes in patients treated with PARP inhibitors and in recurrent HGSC samples. CONCLUSION Our study underscores the importance of considering replication stress markers, such as p-RPA2, alongside HR status in therapeutic planning. This approach has the potential to increase the number of patients receiving effective therapy while reducing unnecessary toxicity. FUNDING The Reproductive Scientist Development Program, GOG Foundation, Pilot Translational and Clinical Studies function of the Washington University Institute of Clinical and Translational Sciences, the Foundation for Barnes-Jewish Hospital, Washington University School of Medicine Dean’s Scholar Program, The Cancer Biology Pathway Training Grant (5T32CA113275-17), The Lucy, Anarcha, and Betsey (L.A.B.) Award from the Department of Obstetrics and Gynecology at Washington University School of Medicine, and Veterans Affairs Office of Research and Development (I01BX006020).
Systematic Review and Meta-analysis: Radiosurgery Outcomes in Cavernous Sinus Meningioma
Camerotte, Raphael , Nogueira, Bernardo Vieira , Lepine, Henrique L. , Montenegro, Thiago S. , Bertani, Raphael, Formentin, Cleiton , Bertani, Raphael , Palavani, Lucca Biolcati , Vilardo, Marina , Mitre, Lucas Pari , Ribeiro, Paulo Victor Zattar, Andreão, Filipi Fim , Torregrossa, Fábio , Moraes, Fábio Ynoe de , Maldaun, Marcos Vinícius Calfat

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803381 Get It

Simvastatin and Rifaximin in Decompensated Cirrhosis
Pose, Elisa , Jiménez, César , Zaccherini, Giacomo , Campion, Daniela , Wit, Koos de , Gananandan, Kohilan , Laleman, Wim , López, Sonia Alonso , Cuyàs, Berta , Ariza, Xavier , T., Ann , Napoleone, Laura , Gratacós‐Ginès, Jordi , Tonon, Marta , Pompili, Enrico , Sánchez‐Delgado, Jordi , Allegretti, Andrew S. , Carol, Marta, Pich, Judit, Martell, Claudia, Joyera, María, Domènech, Gemma, Ríos, José , Torres, Ferràn , Serra‐Burriel, Miquel , Graupera, Isabel , Bañares, Rafael, Beuers, Ulrich , Angeli, Paolo, Alessandria, Carlo , Kamath, Patrick S. , Vargas, Vı́ctor , Ma, Ann T , de Wit, Koos , Vargas, Victor , Jiménez, César , Cuyas, Berta , Torres, Ferran , Piano, Salvatore , Uschner, Frank Erhard , Roux, Olivier , Solé, Cristina , Juanola, Adrià , Morales‐Ruiz, Manuel , Pérez, Martina , Fabrellas, Núria , Joyera, Maria, Hernaez, Ruben , Solà, Elsa , Watson, Hugh R , Soriano, German , Bañares, Rafael , Mookerjee, Rajeshwar P. , Francoz, Claire , Trebicka, Jonel , Angeli, Paolo , Caraceni, Paolo , Vargas, Víctor M., Abraldeṣ, Juan G. , Ginès, Pere

Mayo Clinic

JAMA | February 5, 2025 | Volume: 333 | Issue: 10 | Pages: 864

10.1001/jama.2024.27441 | PMID 39908052 Get It

ImportanceThere are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.ObjectiveTo assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis.Design, Setting, and ParticipantsDouble-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.InterventionsPatients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C.Main Outcomes and MeasuresThe primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection).ResultsAmong the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis.Conclusions and RelevanceThe addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.Trial RegistrationClinicalTrials.gov Identifier: NCT03780673
Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
González, Raul S. , Horton, Rachel K. , Zhang, Xuchen , Graham, Rondell P. , Longacre, Teri A. , Mehrotra, Anupamjit K., Allende, Daniela , McHugh, Kelsey , Shia, Jinru , Westerhoff, Maria , Chen, Wei , Vazzano, Jennifer , Cheema, Hassam, Ma, Changqing , Mannan, Abul Ala Syed Rifat , Agostini‐Vulaj, Diana , Kazemimood, Rossana , Henn, Patrick, Kakar, Sanjay , Choi, Won‐Tak , Adeyi, Oyedele , Allende, Daniela S , McHugh, Kelsey E , Srivastava, Amitabh , Chen, Wei , Vazzano, Jennifer , Swanson, Paul E , Ma, Changqing , Mannan, Abul A S R , Chetty, Runjan , Serra, Stefano , Agostini-Vulaj, Diana , Kazemimood, Rossana , Choi, Won-Tak , Adeyi, Oyedele , Jenkins, Sarah M. , Nagtegaal, Iris D , Gonzalez, Raul S , Graham, Rondell P , Srivastava, Amitabh , Chatterjee, Deyali , Nowak, Klaudia , Kakar, Sanjay , Jenkins, Sarah M, Nagtegaal, Irıs D.

Mayo Clinic

Histopathology | January 31, 2025 | Volume: 86 | Issue: 7 | Pages: 1064-1081

10.1111/his.15412 | PMID 39887413 Get It

AimsWe compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta‐analysis of cohorts and individual case series.Methods and ResultsWe identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome. ASC comprised 0.02% of colorectal cancers in the Dutch database. The median cohort patient ages at resection were 65 and 69 years (North American and Dutch cohorts, respectively), with a roughly equal male:female ratio. The squamous component represented between 5% and 95% of each tumour, with a median of 50%. Tumour‐infiltrating lymphocytes (TILs) were generally low (66%), and tumour budding was often Bd1 (64%). Most cases were pT3 (55%) or pT4 (40%), with nodal metastases in more than half (58%). Twenty‐three cases (43%) metastasized distantly, most commonly to the liver. Mismatch repair (MMR) deficiency was identified in 34% of the cases. Follow‐up was available for 48 patients; 13 (27%) had recurrent disease and 29 (60%) died. A total of 31 patients progressed, with median time to progression of 18 months. Available data for the Dutch cohort revealed largely similar findings, as did review of cases in the literature.ConclusionColorectal ASC usually presents at an advanced stage. Despite high rates of MMR deficiency and low tumour budding, TILs were generally low, and there is a high recurrence rate and poor prognosis.
REFORMS: Consensus-based Recommendations for Machine-learning-based Science
Kapoor, Sayash , Cantrell, Emily M. , Peng, Kenny , Pham, Thanh Hien, Bail, Christopher A. , Gundersen, Odd Erik , Hofman, Jake M. , Hullman, Jessica , Lones, Michael A. , Malik, Momin M. , Nanayakkara, Priyanka , Raji, Inioluwa Deborah , Roberts, Michael , Salganik, Matthew , Stewart, Brandon, Narayanan, Arvind , Poldrack, Russell A , Roberts, Michael , Salganik, Matthew J , Serra-Garcia, Marta , Stewart, Brandon M , Vandewiele, Gilles , Narayanan, Arvind , Malik, Momin , Poldrack, Russell A.

Mayo Clinic

Science Advances | May 1, 2024 | Volume: 10 | Issue: 18 | Pages: No page available

10.1126/sciadv.adk3452 | PMID 38691601 Get It

Machine learning (ML) methods are proliferating in scientific research. However, the adoption of these methods has been accompanied by failures of validity, reproducibility, and generalizability. These failures can hinder scientific progress, lead to false consensus around invalid claims, and undermine the credibility of ML-based science. ML methods are often applied and fail in similar ways across disciplines. Motivated by this observation, our goal is to provide clear recommendations for conducting and reporting ML-based science. Drawing from an extensive review of past literature, we present the REFORMS checklist (recommendations for machine-learning-based science). It consists of 32 questions and a paired set of guidelines. REFORMS was developed on the basis of a consensus of 19 researchers across computer science, data science, mathematics, social sciences, and biomedical sciences. REFORMS can serve as a resource for researchers when designing and implementing a study, for referees when reviewing papers, and for journals when enforcing standards for transparency and reproducibility.
Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
Arnaldi, Dario , Mattioli, Pietro , Raffa, Stefano, Pardini, Matteo , Massa, Federico , Iranzo, Álex , Perissinotti, Andrés , Gaig, Carles , Serradell, Mónica , Muñoz‐Lopetegi, Amaia , Mayà, Gerard , Liguori, Claudio , Fernandes, Mariana , Miyagawa, Toji , Lowe, Val J. , Puligheddu, Monica , Serra, Alessandra , Hu, Michele T., Klein, Johannes , Bes, Frédérik , Kunz, Dieter , Verbizier, Delphine de, Kulcsárová, Kristína , Giuliani, Alessandro , Pagani, Marco , Group, International REM Sleep Behavior Disorder Study, Liguori, Claudio , Miyamoto, Tomoyuki , Kunz, Dieter , Antelmi, Elena , Terzaghi, Michele , Massa, Federico , Maya, Gerard , Puligheddu, Monica , Kulcsarova, Kristina , Mattioli, Pietro , Arnaldi, Dario , Niñerola‐Baizán, Aida , Gaig, Carles , Placidi, Fabio , Chiaravalloti, Agostino , Šonka, Karel , Dušek, Petr , Zogala, David , Trnka, Jiří , Boeve, Bradley F. , Miyamoto, Tomoyuki , Miyamoto, Masayuki , Figorilli, Michela , Hu, Michele T., Cochen De Cock, Valérie , Plazzi, Giuseppe , Antelmi, Elena , Bossert, Irene , Martino, Alessio , Nobili, Flavio Mariano , Morbelli, Silvia , Group, International REM Sleep Behavior Disorder Study

Mayo Clinic

Annals of Neurology | March 11, 2024 | Volume: 95 | Issue: 6 | Pages: 1178-1192

10.1002/ana.26902 | PMID 38466158 Get It

Objective To apply a machine learning analysis to clinical and presynaptic dopaminergic imaging data of patients with rapid eye movement (REM) sleep behavior disorder (RBD) to predict the development of Parkinson disease (PD) and dementia with Lewy bodies (DLB). Method s In this multicenter study of the International RBD study group, 173 patients (mean age 70.5 ± 6.3 years, 70.5% males) with polysomnography‐confirmed RBD who eventually phenoconverted to overt alpha‐synucleinopathy (RBD due to synucleinopathy) were enrolled, and underwent baseline presynaptic dopaminergic imaging and clinical assessment, including motor, cognitive, olfaction, and constipation evaluation. For comparison, 232 RBD non‐phenoconvertor patients (67.6 ± 7.1 years, 78.4% males) and 160 controls (68.2 ± 7.2 years, 53.1% males) were enrolled. Imaging and clinical features were analyzed by machine learning to determine predictors of phenoconversion. Results Machine learning analysis showed that clinical data alone poorly predicted phenoconversion. Presynaptic dopaminergic imaging significantly improved the prediction, especially in combination with clinical data, with 77% sensitivity and 85% specificity in differentiating RBD due to synucleinopathy from non phenoconverted RBD patients, and 85% sensitivity and 86% specificity in discriminating PD‐converters from DLB‐converters. Quantification of presynaptic dopaminergic imaging showed that an empirical z ‐score cutoff of −1.0 at the most affected hemisphere putamen characterized RBD due to synucleinopathy patients, while a cutoff of −1.0 at the most affected hemisphere putamen/caudate ratio characterized PD‐converters. Interpretation Clinical data alone poorly predicted phenoconversion in RBD due to synucleinopathy patients. Conversely, presynaptic dopaminergic imaging allows a good prediction of forthcoming phenoconversion diagnosis. This finding may be used in designing future disease‐modifying trials. ANN NEUROL 2024;95:1178–1192
Abstract 11064: Role of Renin-Angiotensin System Axis in Human Abdominal Aortic Aneurysm
Dugaich, Vinicius Flora, Mestriner, Fabíola , Corsi, Carlos, Mesquita, Carolina D Avila, Francisco, Daniely Franco, Vasconcelos, Jociany, Santos, Cassiana M Mathias Ferreira dos, Campos, Lígia C, Couto, Ariel E, Jordani, Maria CecÃlia C, Jordani, Maria Cecília , Joviliano, Edwaldo Édner , Évora, Paulo Roberto Barbosa , Polonis, Katarzyna , Ribeiro, Maurício Serra , Becari, Christiane

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.11064 Get It

Introduction: Renin-Angiotensin System (RAS) regulates the cardiovascular system and has been implicated in the development of abdominal aortic aneurysm (AAA). RAS modulates function via balancing the ACE/Chymase/AngII-AT1 receptor and ACE-2/Ang(1-7)-Mas receptor axis. Preferential activation of the ACE/Chymase/AngII-AT1 receptor pathway of the RAS contributes to dysregulation of cardiovascular system and disease while the Ang(1-7)-MasR axis contributes to anti-inflammatory pathways. Therefore, identifying the RAS axis mechanism involved in growth, progression, or the risk of rupture in AAA humans could bring a novel treatment perspective. Hypothesis: We hypothesize that in the AAA, the local RAS is altered such as it favours the ACE/AngII/AT1R axis while decreasing the ACE-2/Ang(1-7)/MasR pathway, with consequent AAA development. Objective: We sought to investigate the expression of RAS components in the AAA human aorta. Methods: Aorta tissue from AAA patients (n=21) was collected during the AAA conventional repair surgery, and aorta control aortas were obtained from organ donors (Control, n=11). Protein expression of renin, chymase, ACE, ACE-2 AT1, AT2, and MAS receptors was analyzed by Western Blotting. Results: Our AAA cohort consisted mostly males (76.6% AAA vs. 63.6% Control, p=0.68), smokers or ex-smokers (90.4% AAA vs. 36.3% Control, p=0.002) and most of them had hypertension(71.4% AAA vs. 36.3% Control, p=0.07). Analysis of protein expression in the AAA group showed that ACE and AT1 receptors were upregulated compared with Control (p=0.05; p=0.02, respectively,), while chymase expression was decreased in AAA compared to the control (p=0.03). Additionally, the AAA group showed downregulation in ACE-2 and AT2 compared with Control (respectively, p=0.01, p=0.03). There was no significant difference in the expression of renin and MAS receptors between groups (p=0.52, p=0.41, respectively,). Conclusions: Our data show that the ACE/AT1R axis was upregulated while ACE-2 and AT2 receptors were downregulated in the AAA aorta. Our results implicate local RAS in AAA development and warrant further studies.